指南与共识哮喘

南非哮喘生物制剂合理使用立场声明

Position statement on the appropriate usage of biologic therapies for asthma in South Africa
RSS 订阅 · 指南共识 · 哮喘 · 2026-06-22

南非胸科学会(SATS)发布立场声明,补充2021年哮喘治疗推荐,指导重度哮喘患者生物制剂治疗的适宜评估与启动背景药物要求。声明强调生物制剂适用于以2型高炎症为主的患者,需权衡疗效、副作用与成本,并配套审批流程与重度哮喘登记系统。

要点

  • 生物制剂适用于以2型高炎症为主的重度哮喘患者,可减少急性发作、激素使用和住院。
  • 启动生物制剂前需优化基础哮喘治疗并处理共病,并非所有难治性哮喘均需生物制剂。
  • 南非资源有限,需权衡副作用、证据与成本,通过SATS审批流程和重度哮喘登记支持处方。

核心结论

  • 生物制剂对重度哮喘高效但昂贵,南非需在资源限制下审慎用于2型高炎症患者。
  • 并非所有难治性或名义重度哮喘均需生物制剂,优化基础治疗和共病管理可能足够。
  • 需平衡副作用、证据与成本,避免延迟或拒绝生物制剂对患者造成不公正伤害。

研究设计与样本

  • 南非胸科学会(SATS)资深临床医生撰写的立场声明,补充2021年SATS哮喘治疗推荐。

主要发现

  • 生物制剂(单克隆抗体)可减少重度哮喘患者的疾病负担(急性发作/皮质类固醇使用/住院)。
  • 生物制剂适用于以2型高炎症为主的患者。
  • 生物制剂目前相比标准吸入和口服治疗价格高昂,难以广泛使用。

关键数值与推荐

  • 生物制剂处方需在南非卫生产品监管局注册适应症范围内使用。
  • 启动生物制剂需基于证据明确所需背景药物,并经过适当 preparatory optimisation。
  • SATS已建立生物制剂审批流程并提供表格,同时要求注册于重度哮喘登记系统。

临床怎么用

  • 对考虑生物制剂的重度哮喘患者进行适当评估,确认2型高炎症表型。
  • 启动生物制剂前优化基础哮喘治疗并处理共病。
  • 利用SATS审批流程和重度哮喘登记系统支持处方评估与合理性论证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Afr J Thorac Crit Care Med. 2026 Mar 31;32(1):e4376. doi: 10.7196/AJTCCM.2026.v32i1.4376. eCollection 2026. ABSTRACT Biologic therapies such as monoclonal antibodies are highly effective in reducing disease burden (exacerbations/corticosteroid usage/ hospitalisation) in patients with severe asthma. These medications are currently prohibitively expensive for widespread use compared with standard inhaled and oral therapy. They are indicated for patients with predominantly type 2-high inflammation. Judicious use of biologic therapies in the South African context is imperative given the country's limited healthcare resources. The prescription and clinical use of these therapies within the scope of the South African Health Products Regulatory Authority registered indications therefore require clear guidance and appropriate preparatory optimisation to ensure that the appropriate patients receive the correct medication within an acceptable time frame. Not all patients with difficult-to-treat, or nominally designated as severe, asthma require a biologic therapy in order to be optimally controlled. Simple attention to basic asthma therapeutic principles and treatment of comorbid disease by a clinician with a special interest in asthma may be all that is required. This position statement, written by senior clinicians from the South African Thoracic Society (SATS), is intended to supplement the SATS asthma treatment recommendation of 2021. It provides clear guidance on the appropriate assessment of patients being considered for biologic therapy and clarifies which background medication is required to initiate a biologic therapy in an evidence-based manner. A balanced consideration of side-effects, scientific evidence and cost is essential to prevent unjustified harm to patients by delaying or denying access to biologic therapy. A process to endorse biologic therapy has been created in parallel, and forms are available from SATS, along with registration in the severe asthma registry to support clinicians in appropriate assessment and justification for prescription. PMID: 42327546 | PMC: PMC13277373 | DOI: 10.7196/AJTCCM.2026.v32i1.4376

来源:指南共识 · 哮喘,查看原文。版权归原作者所有。

引用

  1. 指南共识 · 哮喘:Position statement on the appropriate usage of biologic therapies for asthma in South Africa

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。